scholarly journals Usability of a Digital Registry to Promote Secondary Prevention for Peripheral Artery Disease Patients

2020 ◽  
Author(s):  
Alisha P. Chaudhry ◽  
Ronald A. Hankey ◽  
Vinod C. Kaggal ◽  
Huzefa Bhopalwala ◽  
David A. Liedl ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Artery Disease

scholarly journals Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Elena M. Yubero-Serrano ◽  
Juan F. Alcalá-Diaz ◽  
Francisco M. Gutierrez-Mariscal ◽  
Antonio P. Arenas-de Larriva ◽  
Patricia J. Peña-Orihuela ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Cholesterol Efflux ◽  
Newly Diagnosed ◽  
Peripheral Artery ◽  
Cholesterol Efflux Capacity ◽  
Increased Risk ◽  
Artery Disease

Abstract Background Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with either one of them alone. High-density lipoprotein (HDL)-mediated cholesterol efflux capacity (CEC) is found to be inversely associated with an increased risk of incident CHD. However, this association is not established in patients with PAD in the context of secondary prevention. In this sense, our main aim was to evaluate the association between CEC and PAD in patients with CHD and whether the concurrent presence of PAD and T2DM influences this association. Methods CHD patients (n = 1002) from the CORDIOPREV study were classified according to the presence or absence of PAD (ankle-brachial index, ABI ≤ 0.9 and ABI > 0.9 and < 1.4, respectively) and T2DM status. CEC was quantified by incubation of cholesterol-loaded THP-1 cells with the participants' apoB-depleted plasma was performed. Results The presence of PAD determined low CEC in non-T2DM and newly-diagnosed T2DM patients. Coexisting PAD and newly-diagnosed T2DM provided and additive effect providing an impaired CEC compared to non-T2DM patients with PAD. In established T2DM patients, the presence of PAD did not determine differences in CEC, compared to those without PAD, which may be restored by glucose-lowering treatment. Conclusions Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients. Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT00924937. Unique Identifier: NCT00924937

scholarly journals Secondary Prevention and Mortality in Peripheral Artery Disease

Circulation ◽  
2011 ◽  
Vol 124 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Reena L. Pande ◽  
Todd S. Perlstein ◽  
Joshua A. Beckman ◽  
Mark A. Creager
Keyword(s):  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Artery Disease

Aspirin and Secondary Prevention in Peripheral Artery Disease

JAMA ◽  
2009 ◽  
Vol 301 (18) ◽  
pp. 1927 ◽  
Author(s):  
Mary McGrae McDermott ◽  
Michael H. Criqui
Keyword(s):  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Artery Disease

scholarly journals Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial

2019 ◽  
Vol 24 (2) ◽  
pp. 159-161 ◽  
Author(s):  
Siddharth M Patel ◽  
David A Morrow ◽  
Stephen K Kidd ◽  
Erica L Goodrich ◽  
Benjamin M Scirica ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
The Elderly ◽  
Peripheral Artery ◽  
Artery Disease

scholarly journals Comparison of Antiplatelet and Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke in Patients With Peripheral Artery Disease

2013 ◽  
Vol 77 (4) ◽  
pp. 1046-1052 ◽  
Author(s):  
Wen-Hsien Lee ◽  
Chun-Yuan Chu ◽  
Po-Chao Hsu ◽  
Ho-Ming Su ◽  
Tsung-Hsien Lin ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Antithrombotic Therapy ◽  
Peripheral Artery ◽  
Artery Disease

scholarly journals O72: SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PERIPHERAL ARTERY DISEASE PATIENTS

2021 ◽  
Vol 108 (Supplement_1) ◽  
Author(s):  
ST Rashid ◽  
S Bangee
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Nice Guidelines ◽  
Novel Treatments ◽  
Wide Range ◽  
Artery Disease ◽  
Prevention Of Cardiovascular Disease

Abstract Introduction Peripheral artery disease (PAD) is associated with significant cardiovascular morbidity and mortality which can be reduced by the treatment of atherosclerotic risk factors. Recent research demonstrates that novel drugs can significantly enhance PAD outcomes. However, the uptake of these drugs is uncertain. We wished to audit current atherosclerotic management in PAD patients as well as their eligibility for newer drugs - PCSK 9 inhibitors, SGLT2 inhibitors, and DOAC drugs – in accordance with relevant guidelines and trials. Method 100 PAD inpatients and outpatients seen at a teaching hospital in the UK within the month of March 2019 were assessed. Medications from PAD patients were recorded from hospital records and patient histories were assessed for secondary prevention of cardiovascular disease - lipids, blood pressure, diabetic control, and atherothrombotic prevention. Result showed that compliance with NICE guidelines had a wide range – from 19% of outpatients on correct lipid control to 89% of inpatients on optimal atherothrombotic management. Based on the best evidence of eligibility: 0 of 41 eligible patients were taking PCSK9 Inhibitors, 1 out of the 71 was on an SGLT 2 inhibitor and 6 of 98 patients were on Rivaroxaban. Conclusion This audit shows adherence to NICE guidelines is variable for secondary prevention of atherosclerosis in PAD patients. Furthermore, very few novel treatments had been prescribed for suitable patients. Overall, prescribing for PAD risk factor management can be significantly improved. A solution could be dedicating risk factor clinics led by nurses, pharmacists or physicians. Take-home message Steps need to be taken to prevent cardiovascular disease in peripheral arterial disease patients. Steps include improvements in the following of guidelines, exploration of novel treatments, and the introduction of special risk factor clinics focused on improving the prognosis of the patients.

Sign in / Sign up

Export Citation Format

Share Document